Working... Menu
Trial record 56 of 2511 for:    "Plasma Cell Neoplasm"

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00744354
Recruitment Status : Terminated (Drugs unavailable- study terminated 1/2/18)
First Posted : September 1, 2008
Last Update Posted : January 18, 2018
Merck Sharp & Dohme Corp.
Millennium Pharmaceuticals, Inc.
Ortho Biotech, Inc.
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

Brief Summary:

RATIONALE: Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of multiple myeloma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving doxorubicin hydrochloride liposome together with vorinostat and bortezomib may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat and to see how well it works when given together with bortezomib and doxorubicin hydrochloride liposome in treating patients with relapsed or refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma and Plasma Cell Neoplasm Drug: bortezomib Drug: pegylated liposomal doxorubicin hydrochloride Drug: vorinostat Phase 1

Detailed Description:



  • To determine the maximum tolerated dose of vorinostat when added to the standard regimen of bortezomib and pegylated liposomal doxorubicin hydrochloride in patients with relapsed or refractory multiple myeloma.
  • To identify the dose-limiting toxicities of this regimen in these patients.


  • To gain preliminary evidence of antitumor activity of this regimen in these patients.
  • To assess the degree of proteasome inhibition achieved with this regimen in these patients.
  • To evaluate the accumulation of acetylated alpha-tubulin after treatment with vorinostat.
  • To evaluate overall survival, time to progression, and progression-free survival of patients treated with this regimen.

OUTLINE: This is a multicenter, dose escalation study of vorinostat.

Patients receive oral vorinostat once daily on days 1,2; 4,5; 8, 9; 11, 12; bortezomib IV on days 1, 4, 8, and 11, and pegylated liposomal doxorubicin hydrochloride IV on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for proteasome inhibition assays and acetylated alpha-tubulin studies.

After completion of study treatment, patients are followed at 1 and 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Study Start Date : October 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : April 2015

Arm Intervention/treatment
Experimental: Non-Randomized Open Label Single Arm
Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
Drug: bortezomib
Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
Other Name: Velcade

Drug: pegylated liposomal doxorubicin hydrochloride
Intravenous infusion, 30mg/m2, Day 4, each cycle
Other Name: Doxil

Drug: vorinostat
Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
Other Name: Zolinza

Primary Outcome Measures :
  1. Maximum tolerated dose of vorinostat [ Time Frame: 4 years ]

Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: 5 years ]
  2. Duration of response [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of multiple myeloma

    • Relapsed or refractory disease


  • ECOG performance status 0-2
  • Life expectancy ≥ 3 months
  • ANC ≥ 1.0 x 10^9/L (no granulocyte growth factor support, e.g., G-CSF or GM-CSF allowed)
  • Platelet count ≥ 100 x 10^9/L (erythropoietin allowed, no platelet or RBC transfusion within the past 2 weeks)
  • Hemoglobin ≥ 8 g/dL (erythropoietin allowed, no platelet or RBC transfusion within the past 2 weeks)
  • Creatinine clearance ≥ 30 mL/min
  • AST or ALT ≤ 2.5 times upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after completion of study treatment
  • LVEF ≥ 45% by MUGA or ECHO
  • Symptomatic neuropathy < grade 2
  • No known history of HIV
  • No active or serious infection, medical or psychiatric illness that would preclude study participation
  • No active hepatitis B or C infection
  • No other prior or concurrent malignancy except for adequately treated basal cell or squamous cell carcinoma of the skin, in situ malignancy, low-risk prostate cancer after curative therapy, or other cancer for which the patient has been disease-free for ≥ 3 years
  • No history of hypersensitivity reaction to bortezomib or any of its components (boron, mannitol), vorinostat, doxorubicin hydrochloride, or any of the components of PLD
  • No serum potassium ≤ 3.0 or serum magnesium ≤ 1.6 that cannot be corrected with supplementation are excluded
  • Patients must have adequate cardiovascular function, defined by all of the following:

    • No EKG evidence of active, clinically significant conduction system abnormalities
    • No EKG evidence of QTc prolongation > grade 2
  • NOTE: Any EKG abnormality at screening has to be documented by the investigator as not medically significant.


  • No limit to number of prior treatment regimens
  • At least 30 days since prior therapy and recovered
  • At least 3 months since prior autologous stem cell transplantation and recovered
  • Prior allogeneic stem cell or bone marrow transplantation allowed provided the following criteria are met:

    • More than 1 year since transplantation
    • No longer receiving immunosuppressive therapy or treatment for graft-versus-host disease (GVHD) prophylaxis
    • No active GVHD
    • No active, uncontrolled infections
  • No major surgery within the past 3 weeks
  • No prior anthracycline dose > 360 mg/m^2 for doxorubicin hydrochloride (including pegylated liposomal doxorubicin hydrochloride [PLD]) or 720 mg/m^2 for epirubicin hydrochloride
  • No prior or concurrent histone deacetylase inhibitor (e.g., valproic acid)
  • No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) during course 1
  • No other concurrent investigational or anticancer agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00744354

Layout table for location information
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
United States, North Carolina
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7295
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096
Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme Corp.
Millennium Pharmaceuticals, Inc.
Ortho Biotech, Inc.
Layout table for investigator information
Principal Investigator: Brandi Reeves, MD UNC Lineberger Comprehensive Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: UNC Lineberger Comprehensive Cancer Center Identifier: NCT00744354     History of Changes
Other Study ID Numbers: LCCC 0715
08-1073 ( Other Identifier: Office of Human Research Ethics )
First Posted: September 1, 2008    Key Record Dates
Last Update Posted: January 18, 2018
Last Verified: January 2018

Keywords provided by UNC Lineberger Comprehensive Cancer Center:
refractory multiple myeloma
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Histone Deacetylase Inhibitors